<DOC>
	<DOCNO>NCT01294735</DOCNO>
	<brief_summary>This non-randomized two-part study MK-4827 give temozolomide participant advanced cancer . In Part A study , dose-limiting toxicity ( DLTs ) maximum tolerate dose ( MTD ) MK-4827 combine temozolomide find increase MK-4827 dose level successive cohort . In Part B study , participant advance glioblastoma multiforme advance melanoma enrol evaluate tolerability efficacy MK-4827 + temozolomide combination .</brief_summary>
	<brief_title>Study Safety Efficacy MK-4827 Given With Temozolomide Participants With Advanced Cancer ( MK-4827-014 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Inclusion criterion Part A Participants histologicallyconfirmed advanced solid tumor fail respond standard therapy , progressed standard therapy , standard therapy exist . Part B Participants must histologicallyconfirmed recurrent glioblastoma multiforme ( GBM ) radiographic evidence progression/recurrence disease , two prior treatment regimen ( include temozolomide bevacizumab ) recurrent disease . OR Participants must histologicallyconfirmed recurrent metastatic melanoma participant receive two prior therapy . Participants must receive prior treatment cytotoxic chemotherapy include temozolomide , dacarbazine , PARP inhibitor . Part A Part B Participants Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Participants must adequate organ function . Women childbearing potential male participant must agree use adequate method contraception start first dose study drug 90 day last dose study drug . Participant history prior malignancy exception glioma ( secondary GBM allow ) , cervical intraepithelial neoplasia , basal cell carcinoma skin , adequately treat localized prostate carcinoma ProstateSpecific Antigen ( PSA ) &lt; 1.0 ; undergone potentially curative therapy evidence disease five year , deem low risk recurrence his/her treat physician . Participant least one measurable metastatic recurrent lesion . Exclusion criterion Participant chemotherapy , radiotherapy , biological therapy within four week prior study Day 1 ( six week nitrosoureas mitomycin C ) recover adverse event due agent administer four week earlier . Participants know symptomatic progressive Central Nervous System ( CNS ) metastases and/or carcinomatous meningitis . Participant prior exposure PARP inhibitor . Prior exposure temozolomide allow participant GBM , provide receive adjuvant set GBM progression completion adjuvant temozolomide treatment treatmentfree interval â‰¥ 3 month . Participant significant uncontrolled cardiovascular disease , include New York Heart Association ( NYHA ) Class IIIIV heart failure , unstable angina , myocardial infarction within last six month . Participant breastfeeding . Participant known Human Immunodeficiency Virus ( HIV ) positive . Participant active Hepatitis B C. Participant symptomatic ascites pleural effusion . Participant requirement concurrent treatment immunosuppressive agent . Participant must prior radiation therapy 30 % hte bone marrow must recover least 3 week hematologic toxicity prior radiotherapy . Participant prior stem cell bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Temozolomide</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>melanoma</keyword>
	<keyword>advanced neoplasm</keyword>
</DOC>